Latest news
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 15:14:00 GMTGilead reports strong Q2 driven by HIV portfolio - EMJEMJ · Thu, 06 Aug 2026 16:39:36 GMTGILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 15:22:00 GMTGilead raises full-year guidance on 8% Q2 sales growth, eyes three near-term regulatory approvals - AllSciAllSci · Wed, 05 Aug 2026 14:17:35 GMTFor the first time, Gilead's HIV prevention franchise crosses $1B in quarterly sales - FirstWord PharmaFirstWord Pharma · Wed, 05 Aug 2026 13:56:57 GMTGilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss - The Pharma LetterThe Pharma Letter · Wed, 05 Aug 2026 13:02:31 GMTGilead Raised HIV Guidance on Its Q2 Earnings Call. Here’s What That Means for GILD Stock. - TIKR.comTIKR.com · Wed, 05 Aug 2026 10:39:48 GMTGilead Sciences (NASDAQ:GILD) Issues Earnings Results, Beats Estimates By $0.51 EPS - MarketBeatMarketBeat · Wed, 05 Aug 2026 00:14:20 GMT